Immunotherapy Development
Immuno-oncology stands at the forefront of groundbreaking research, dedicated to developing therapies that harness the power of the immune [...]
Cellular Toxicity
Cellular toxicity is a major problem and can result in organ dysfunction and cause many severe health problems. Various [...]
Imaging Scientist
Mike Johnson2021-01-05T13:19:42-05:00At Visikol, our mission is to accelerate the discovery and development of therapeutics through transforming tissues into quantitative data [...]
Targeting Fibrosis
Fibrosis is the pathological overaccumulation of excess connective tissue as a result of imbalances during the body’s healing processes [...]
Are You Choosing the Right Cell Viability Assay?
Viability is a ubiquitous endpoint in cell-based assays. The results make a general claim about the current state of [...]
Visikol® HISTO™ and Abcam Combo Kits Featured on Labmate
Mike Johnson2019-07-22T12:27:22-05:00In early 2019, Visikol partnered with Abcam to provide researchers with tissue clearing kits for easy-to-use, rapid and high-quality [...]
Literature Review: Clarification and Confocal Imaging of the Nonhuman Primate Placental Micro-Anatomy
Mike Johnson2019-07-24T13:06:23-05:00Visikol is the leader in 3D tissue imaging and transforming tissues into quantitative three-dimensional insights. In addition to its [...]
Quantitative Digital Pathology – 3Screen™
Mike Johnson2019-07-24T13:11:29-05:00Many researchers in the preclinical space who employ histological staining methods are interested in getting more information from their [...]
Intern with Visikol this summer!
Mike Johnson2019-02-21T01:30:51-05:00Visikol is currently looking for a summer business intern to the join the team starting in May. We are looking [...]
Visikol Secures New Round of Funding Led by Industry Experienced Executives
Mike Johnson2019-02-21T01:30:51-05:00Funds will be used to help scale Visikol’s 3Screen™ drug discovery service business which combines quantitative histopathology with the patented [...]